Search results for "Histocompatibility"

showing 10 items of 473 documents

Identification of a Kd-restricted antigenic peptide encoded by murine cytomegalovirus early gene M84

2000

The two sister cytomegaloviruses (CMVs), human and murine CMV, have both evolved immune evasion functions that interfere with the major histocompatibility complex class I (MHC-I) pathway of antigen processing and presentation and are effectual in the early (E) phase of virus gene expression. However, studies on murine CMV have shown that E-phase immune evasion is leaky. An E-phase protein involved in immune evasion, namely m04-gp34, was found to simultaneously account for an antigenic peptide presented by the MHC-I molecule Dd. Recent work has demonstrated the induction of protective immunity specific for the E-phase protein M84-p65, one of two murine CMV homologues of the human CMV matrix …

MuromegalovirusPeptideBiologyMajor histocompatibility complexImmediate-Early ProteinsMiceOpen Reading FramesImmune systemVirologyAnimalsAmino Acid SequenceLymphocyte CountAntigens ViralGenes Immediate-EarlyGeneAntigenic peptidechemistry.chemical_classificationMice Inbred BALB CViral matrix proteinAntigen processingH-2 AntigensVirologyMolecular biologyPeptide FragmentschemistryCytomegalovirus earlybiology.proteinImmunologic MemoryT-Lymphocytes CytotoxicJournal of General Virology
researchProduct

Major Histocompatibility Complex Class I Allele-specific Cooperative and Competitive Interactions between Immune Evasion Proteins of Cytomegalovirus

2002

Cytomegaloviruses (CMVs) deploy a set of genes for interference with antigen presentation in the major histocompatibility complex (MHC) class I pathway. In murine CMV (MCMV), three genes were identified so far: m04/gp34, m06/gp48, and m152/gp40. While their function as immunoevasins was originally defined after their selective expression, this may not necessarily reflect their biological role during infection. The three immunoevasins might act synergistically, but they might also compete for their common substrate, the MHC class I complexes. To approach this question in a systematic manner, we have generated a complete set of mutant viruses with deletions of the three genes in all seven pos…

Muromegalovirusmurine cytomegalovirusImmunologyAntigen presentationGenes MHC Class IMutagenesis (molecular biology technique)Context (language use)Virus ReplicationMajor histocompatibility complexPolymerase Chain ReactionArticleMiceViral ProteinsMuromegalovirusMHC class IEscherichia coliAnimalsImmunology and AllergyGeneAllelesBACimmune evasionGlycoproteinsGeneticsMice Inbred BALB CMembrane GlycoproteinsbiologyalleleFibroblastsbiology.organism_classificationViral replicationMHC class IIbiology.proteinCarrier ProteinsJournal of Experimental Medicine
researchProduct

Anti-p53-directed immunotherapy of malignant disease

2004

Mutation and aberrant expression of the p53 tumour suppressor protein are the most frequent molecular alterations in human malignancy. Peptides derived from the p53 protein and presented by major histocompatibility complex molecules for T-cell recognition could serve as universal tumour-associated antigens for cancer immunotherapy. Because p53 normally functions as a ubiquitously expressed self-protein, controlling cell-cycle progression and apoptosis, it also represents a paradigm target molecule for tumour-reactive yet self-antigen-specific T cells. Tailoring p53-based cancer immunotherapy thus requires both interference with p53-specific self-tolerance and induction of the entire reperto…

MutationT-Lymphocytesmedicine.medical_treatmentT-cell receptorGenetic TherapyImmunotherapyBiologymedicine.disease_causeMajor histocompatibility complexCell therapyGenes T-Cell ReceptorCancer immunotherapyAntigenNeoplasmsmedicineCancer researchbiology.proteinHumansMolecular MedicineImmunotherapyTumor Suppressor Protein p53ReceptorMolecular BiologyExpert Reviews in Molecular Medicine
researchProduct

Loss of Nrf2 in bone marrow-derived macrophages impairs antigen-driven CD8+ T cell function by limiting GSH and Cys availability

2015

NF-E2-related factor 2 (Nrf2), known to protect against reactive oxygen species, has recently been reported to resolve acute inflammatory responses in activated macrophages. Consequently, disruption of Nrf2 promotes a proinflammatory macrophage phenotype. In the current study, we addressed the impact of this macrophage phenotype on CD8(+) T cell activation by using an antigen-driven coculture model consisting of Nrf2(-/-) and Nrf2(+/+) bone marrow-derived macrophages (BMDMΦ) and transgenic OT-1 CD8(+) T cells. OT-1 CD8(+) T cells encode a T cell receptor that specifically recognizes MHC class I-presented ovalbumin OVA(257-264) peptide, thereby causing a downstream T cell activation. Interes…

NF-E2-Related Factor 2OvalbuminAntiporterT cellBlotting WesternReceptors Antigen T-CellApoptosisMice TransgenicCD8-Positive T-LymphocytesBiologyReal-Time Polymerase Chain Reactionenvironment and public healthBiochemistryAntioxidantsImmunoenzyme TechniquesMicechemistry.chemical_compoundBone MarrowPhysiology (medical)MHC class ImedicineAnimalsCytotoxic T cellRNA MessengerCells CulturedCell ProliferationMice KnockoutReverse Transcriptase Polymerase Chain ReactionGCLMMacrophagesHistocompatibility Antigens Class IGlutathionerespiratory systemFlow CytometryGlutathioneMolecular biologyMice Inbred C57BLOxidative Stressmedicine.anatomical_structurechemistrybiology.proteinCystineReactive Oxygen SpeciesIntracellularCD8Signal TransductionFree Radical Biology and Medicine
researchProduct

Anomalous alterations affecting microglia in the central nervous system of a fetus at 12 weeks of gestation: case report.

2003

We report here on the first documented case of profound alterations specifically affecting the microglial population within the nervous system during the fetal period. This case, derived at gestational week 12, was one amongst a series of second trimester brains currently being investigated with respect to microglial colonization of the human fetal brain. No significant pathological alterations could be identified upon gross macroscopy or following microscopic analysis of serial brain sections stained with cresyl fast violet (Nissl). By contrast, sections stained immunohistochemically to detect MHC class II (CR3/43) and CD68 (PG-M1) antigens revealed a marked pathological change in the morp…

Nervous systemCentral Nervous SystemPathologymedicine.medical_specialtyCentral nervous systemThalamusPopulationAntigens Differentiation MyelomonocyticGestational AgeBiologyPathology and Forensic MedicineMajor Histocompatibility ComplexCellular and Molecular Neurosciencesymbols.namesakeEmbryonic and Fetal DevelopmentFetusAntigens CDPregnancymedicineHumanseducationFetuseducation.field_of_studyMicrogliaStaining and LabelingCerebrumImmunohistochemistrymedicine.anatomical_structureNissl bodysymbolsFemaleNeurology (clinical)MicrogliaActa neuropathologica
researchProduct

Neurons as targets for T cells in the nervous system

2013

International audience; Accumulating evidence shows that T cells penetrate the central nervous system (CNS) parenchyma in several autoimmune, infectious, and degenerative neurological diseases. The structural and functional consequences for CNS neurons of their encounter with activated T cells have been investigated in several experimental systems, including ex vivo co-cultures, electrophysiology, and in vivo imaging. Here, we review the modalities of neuron/T cell interactions. We substantiate the contention that T cells are directly responsible for neuronal damage in a large number of neurological diseases and discuss mechanisms of neuronal damage mediated by distinct T cell subsets, the …

Nervous systemMultiple SclerosisT cell[SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyAntigen presentationCentral nervous systemInflammationAdaptive ImmunityBiology[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Nervous System03 medical and health sciences0302 clinical medicineT-Lymphocyte Subsets[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]medicineAnimalsHumansEncephalitis Viral030304 developmental biologyNeuronsAntigen PresentationImmunity Cellular0303 health sciencesGeneral NeuroscienceHistocompatibility Antigens Class Iapoptosis[SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/NeurobiologyT cellNeurodegenerative DiseasesAcquired immune systemcentral nervous systemneuron3. Good healthmedicine.anatomical_structurenervous system[SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunologyinflammation[SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunologyencephalomyelitisNeuronNervous System Diseasesmedicine.symptomNeuroscience030217 neurology & neurosurgeryEx vivo
researchProduct

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

2013

Background Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line. Results We found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class…

Neuroblastoma RAS viral oncogene homologmedicine.disease_causeMajor histocompatibility complexPolymorphism Single NucleotideProto-Oncogene Proteins p21(ras)TranscriptomeMiceAntigenAntigens NeoplasmCDKN2ACell Line TumorMHC class ImedicineGeneticsAnimalsCancer modelsComputational immunologyCyclin-Dependent Kinase Inhibitor p16Mice Inbred BALB CMHC class IIbiologyCarcinomaHigh-Throughput Nucleotide SequencingSequence Analysis DNAColorectal cancerMolecular biologyColonic Neoplasmsbiology.proteinImmunotherapyKRASTranscriptomeResearch ArticleBiotechnologyBMC Genomics
researchProduct

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses

2008

AbstractThe tyrosine kinase inhibitors sorafenib and sunitinib are approved for the treatment of patients with malignant diseases. To analyze the possible use of these compounds in combination with immunotherapeutic approaches, we analyzed the effects of both inhibitors on the immunostimulatory capacity of human dendritic cells (DCs) and the induction of primary immune responses in vivo. Sorafenib, but not sunitinib, inhibits function of DCs, characterized by reduced secretion of cytokines and expression of CD1a, major histocompatibility complex, and costimulatory molecules in response to TLR ligands as well as by their impaired ability to migrate and stimulate T-cell responses. These inhib…

NiacinamideSorafenibIndolesPyridinesImmunologyAntineoplastic AgentsApoptosisCD8-Positive T-LymphocytesPharmacologyBiologyurologic and male genital diseasesMajor histocompatibility complexT-Lymphocytes RegulatoryBiochemistryPeripheral blood mononuclear cellMiceImmune systemCell MovementIn vivoSunitinibmedicineAnimalsHumansCytotoxic T cellPyrrolesCells CulturedSunitinibPhenylurea CompoundsBenzenesulfonatesGranulocyte-Macrophage Colony-Stimulating FactorDextransDendritic CellsCell BiologyHematologySorafenibEndocytosisfemale genital diseases and pregnancy complicationsMice Inbred C57BLToll-Like Receptor 4biology.proteinCytokinesFemaleInterleukin-4Lymphocyte Culture Test MixedTyrosine kinaseCell DivisionSignal Transductionmedicine.drugBlood
researchProduct

Hepatocellular carcinoma in a patient with hereditary hemochromatosis and noncirrhotic liver. A case report.

1999

A case of a 62-year-old patient with hereditary hemochromatosis is reported, who developed hepatocellular carcinoma (HCC) in the absence of cirrhosis and other potential risk factors for HCC. Occurrence of HCC in patients with genetic hemochromatosis and noncirrhotic liver is a rare event which has previously been described only six times and appears to be limited to male patients.

Noncirrhotic liverMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularIronGenetic hemochromatosisHemosiderinGastroenterologyPathology and Forensic MedicineHLA AntigensInternal medicineCarcinomamedicineHumansIn patientHemochromatosis ProteinneoplasmsPotential riskbusiness.industryHistocompatibility Antigens Class ILiver NeoplasmsMembrane ProteinsCell BiologyMiddle Agedmedicine.diseasedigestive system diseasesHepatocellular carcinomaHereditary hemochromatosisHemochromatosisbusinessPathology, research and practice
researchProduct

A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation.

2013

Thymidine phosphorylase (TYMP), an enzyme involved in nucleotide synthesis, has been implicated in critical biological processes such as DNA replication, protection against mutations, and tissue repair. In this work, we retrospectively evaluated the influence of a polymorphism in the TYMP gene (rs112723255; G/A) upon the outcome of 448 patients subjected to allogeneic stem cell transplantation (allo-SCT) from an human leukocyte antigen (HLA)-identical sibling donor. The TYMP genotype of patients correlated with overall survival—carriers of the minor allele (A) being at an increased risk of dying after transplantation (hazard ratio, HR = 1.9; P = 0.004). This effect was mostly due to differe…

OncologyAdultMalemedicine.medical_specialtyTime FactorsAdolescentGenotypeGraft vs Host DiseaseHuman leukocyte antigenDiseaseBiologyRisk FactorsInternal medicineGenotypemedicineHumansTransplantation HomologousAlleleChildAllelesAgedRetrospective StudiesThymidine PhosphorylasePolymorphism GeneticHistocompatibility TestingSiblingsHazard ratioInfantHematologyMiddle AgedMinor allele frequencyTransplantationSurvival RateChild PreschoolHematologic NeoplasmsImmunologyChronic DiseaseFemaleComplicationStem Cell TransplantationAmerican journal of hematology
researchProduct